News Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-01-16 EST			5-day change	1st Jan Change
81.99 ^USD	-3.26%		+2.21%	-6.13%

01-13	Protagonist Therapeutics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 08:15 AM
01-05	Takeda and Protagonist Announce Submission of New Drug Application for Rusfertide for Treatment of Polycythemia Vera	CI

01-13	Protagonist Therapeutics, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-13-2026 08:15 AM
01-05	Takeda and Protagonist Announce Submission of New Drug Application for Rusfertide for Treatment of Polycythemia Vera	CI
01-05	Truist Adjusts Price Target on Protagonist Therapeutics to $110 From $88, Maintains Buy Rating	MT
01-05	Takeda Pharmaceutical, Protagonist Submit FDA Application for Rusfertide for Polycythemia Vera Treatment	MT
12-06	Protagonist Therapeutics, Inc. and Takeda Pharmaceutical Company Limited Present Longer-Term Data At ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera	CI
11-06	Protagonist Therapeutics : Reports Third Quarter 2025 Financial Results and Provides Corporate Update	PU
11-06	Protagonist Therapeutics Q3 net loss widens to $39.3 mln	RE
11-06	Earnings Flash (PTGX) Protagonist Therapeutics, Inc. Reports Q3 Revenue $4.7M, vs. FactSet Est of $3.8M	MT
11-06	Protagonist Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-06	Protagonist Therapeutics: Q3 Earnings Snapshot	AQ
25-10-28	Wedbush Raises Price Target on Protagonist Therapeutics to $86 From $70, Keeps Outperform Rating	MT
25-10-28	Truist Raises Price Target on Protagonist Therapeutics to $88 From $76, Keeps Buy Rating	MT
25-10-27	Protagonist Therapeutics Says Icotrokinra Showed 'Meaningful' Outcomes in Ulcerative Colitis Phase 2 Trial	MT
25-10-21	Big Pharma Just Put Peptides Back on the Map - Which Players Are Still Under the Radar?	AQ
25-10-14	Protagonist Therapeutics Insider Sold Shares Worth $979,480, According to a Recent SEC Filing	MT
25-10-10	Deals of the day-Mergers and acquisitions	RE
25-10-10	Sector Update: Health Care Stocks Decline Friday Afternoon	MT
25-10-10	Johnson & Johnson Reportedly in Talks to Buy Protagonist Therapeutics	CI
25-10-10	Top Midday Gainers	MT
25-10-10	Johnson & Johnson in Talks to Acquire Protagonist Therapeutics	MT
25-10-10	Top Midday Stories: Trump Threatens 'Massive' Tariff Raise on China; Nvidia Chips Face Higher Scrutiny at China Customs	MT
25-10-10	Protagonist Therapeutics Leaps on Report of Possible J&J Deal	DJ
25-10-10	Johnson & Johnson in Talks to Acquire Protagonist Therapeutics	MT
25-10-10	Johnson & Johnson in Talks to Acquire Protagonist Therapeutics, WSJ Reports	MT
25-10-10	Johnson & Johnson in talks to acquire Protagonist Therapeutics, source says	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

News Protagonist Therapeutics, Inc.

Equities

PTGX

US74366E1029

Biotechnology & Medical Research

Filters